Herpes simplex infectious disease
MONDO:0004609A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)
Also known as: Simplexvirus caused disease or disorder, Simplexvirus disease or disorder, Simplexvirus infectious disease, herpes simplex, herpes simplex complex, herpes simplex infection, herpes simplex viral infection
38 clinical trials for this condition and its sub-types, 15 tagged with Herpes simplex infectious disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Herpes simplex infectious disease
-
Genital herpes 8 trials
2 sub-types
-
Herpes simplex type 2 infectious disease 5 trials · 8 incl. sub-types
2 sub-types
-
Herpes labialis 5 trials
2 sub-types
-
2 sub-types
-
Herpes simplex virus keratitis 1 trial · 4 incl. sub-types
2 sub-types
- Endotheliitis 2 trials
- Stromal keratitis 1 trial
-
Herpes simplex encephalitis 2 trials
-
Herpes simplex dermatitis 0 trials
-
Herpetic whitlow 0 trials
-
New mRNA vaccine aims to shield transplant patients from dangerous virus
Vaccine OngoingThis study tests an mRNA vaccine (mRNA-1647) to prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. About 84 participants will receive either the vaccine or a placebo. The goal is to see if the vaccine can safely prevent CMV after stopping stand…
Phase 2 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Aug 12, 2026 00:00 UTC
-
New shingles vaccine trial aims for safer protection in adults 40+
Vaccine By invitation onlyThis early-stage trial tests a new shingles vaccine in 120 adults aged 40 and older. The main goal is to check safety and side effects at different doses, while also looking at how well the vaccine triggers an immune response. Participants receive either the vaccine or a placebo,…
Phase 1 • Sponsor: Changchun BCHT Biotechnology Co. • Aim: Vaccine
Last updated Jun 27, 2026 13:05 UTC
-
New mRNA vaccine trial aims to stop genital herpes
Vaccine By invitation onlyThis early-stage study is testing an mRNA vaccine designed to protect against genital herpes (HSV-2) in 144 healthy adults aged 18 to 55. The vaccine is given in different doses to people who have and have not been exposed to the virus before. The main goal is to check for side e…
Phase 1 • Sponsor: Changchun BCHT Biotechnology Co. • Aim: Vaccine
Last updated Jun 27, 2026 08:09 UTC
-
BioNTech launches first human test of mRNA herpes vaccine
Vaccine OngoingThis early-stage trial tests an mRNA vaccine called BNT163, designed to prevent genital herpes caused by HSV-2 and possibly HSV-1. About 318 healthy adults and people with recurrent genital herpes will receive the vaccine or a placebo. The main goal is to check safety and measure…
Phase 1 • Sponsor: BioNTech SE • Aim: Vaccine
Last updated Jun 27, 2026 07:55 UTC
-
New hope for kidney transplant patients: extended drug trial targets rejection
Disease control By invitation onlyThis study offers kidney transplant patients with antibody-mediated rejection (AMR) the chance to receive felzartamab for up to 4 more years. AMR occurs when the immune system attacks the new kidney. The main goal is to check long-term safety and monitor kidney health through bio…
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a donor corneal disc heal scarred eyes from herpes?
Disease control By invitation onlyThis trial tests whether implanting a thin disc of donor cornea tissue — called a stromal lenticule — can improve corneal transparency and vision in people with herpetic stromal keratitis, a herpes infection that scars the cornea. The lenticule contains stem cells and other livin…
Sponsor: Eye Hospital Pristina Kosovo • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Experimental virus therapy for childhood brain tumors tested with radiation
Disease control CancelledThis study aimed to test an experimental virus therapy called G207, combined with a single dose of radiation, in children whose high-grade glioma had come back after prior treatment. The virus was injected directly into the brain tumor to kill cancer cells and trigger an immune r…
Phase 2 • Sponsor: Pediatric Brain Tumor Consortium • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Scientists compare immune responses to viral and bacterial infections in ICU patients
Knowledge-focused OngoingThis study looks at how the immune system of patients in the intensive care unit (ICU) responds to severe infections caused by viruses or bacteria. Researchers will take extra blood samples from 38 adults to analyze immature granulocytes, a type of immune cell. The goal is to see…
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC